Magstim

Magstim operates at the intersection of medical devices, clinical neurotechnology, and neuroscience research. Its core position is built around TMS stimulators and therapy packages, but its portfolio extends into EEG, tDCS, neuroimaging, analysis software, and integrated neuromodulation. The company differentiates through a single-vendor TMS-EEG proposition: its systems are designed to synchronize stimulation and neural-signal acquisition while reducing TMS artifacts. Its portfolio includes Magstim BiStim, 200, and Rapid systems, alongside EGI high-density EEG platforms supporting 32 to 256 channels and Net Station 6 software. Magstim reports more than 15,000 studies citing its TMS systems and more than 4,500 peer-reviewed publications involving EGI EEG systems. The July 2025 FDA clearance and December 2024 UKCA approval broaden its clinical relevance beyond research. Relative to standalone stimulation or EEG vendors, Magstim’s clearest strategic distinction is the combination of stimulation hardware, EEG acquisition, artifact reduction, time-locking, and clinical support.

Magstim’s trajectory shows a gradual expansion from a specialist TMS hardware supplier into a broader neurotechnology platform. Founded in 1990, the company now combines TMS stimulators and coils with EEG, tDCS, neuroimaging, analysis, and integrated research workflows. The July 2020 acquisition of Electrical Geodesics’ product portfolio was a key inflection point, adding high-density EEG capabilities and supporting a more integrated TMS-EEG proposition. Product activity then moved toward clinical commercialization: Horizon Inspire received UKCA approval on December 5, 2024 for use in UK clinics treating major depressive disorder, OCD, and anxiety. On July 9, 2025, an updated Rapid TMS system received FDA clearance for research and clinical use in the United States, including pain treatment. The portfolio also includes Magstim Connect and Magstim Analytics for treatment-data management, tracking, planning, and monitoring. Growth therefore appears product- and regulatory-led, with clinical adoption and integrated data workflows as the main observable expansion vectors.